Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 471 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups
Patents for C07D 471 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups (64,559)
03/2005
03/03/2005US20050049253 Substituted quinolinone derivatives and methods of use
03/03/2005US20050049252 Treating arthritis, pain and cancer; cyclooxygenase-2 inhibitors
03/03/2005US20050048315 Such as 4-(dicyanomethylene)-2-{p-(dialkylamino)styryl}-6-{p-(diarylamino)styryl}-4H-pyran; improved carrier transportation and exhibits long wavelength light
03/03/2005CA2536313A1 Fused pyrimidine derivative and use thereof
03/03/2005CA2536095A1 Aminobenzimidazole derivatives
03/03/2005CA2535644A1 Substituted pyrimdinone derivatives and methods of use
03/03/2005CA2535120A1 Hydroxylamine substituted imidazo-containing compounds
03/03/2005CA2535117A1 Oxime substituted imidazo-containing compounds
03/03/2005CA2533435A1 Mitotic kinesin inhibitors
03/02/2005EP1510518A2 Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha levels
03/02/2005EP1510516A1 Pyrazole compound and medicinal composition containing the same
03/02/2005EP1509592A1 Ligand and complex for catalytically bleaching a substrate
03/02/2005EP1509537A2 Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds and the compounds as such
03/02/2005EP1509523A2 Triazaspiro compounds useful for treating or preventing pain
03/02/2005EP1509522A1 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands
03/02/2005EP1509521A2 1h-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases
03/02/2005EP1509520A1 Use of benzo(c)quinolizinium derivatives for the treatment of diseases that are linked to smooth muscle cell constriction
03/02/2005EP1509518A1 Calcium receptor modulating agents
03/02/2005EP1509497A1 Calcium receptor modulating arylalkylamines
03/02/2005EP1509491A1 Intermediate products, methods for their preparation and use thereof
03/02/2005EP1509228A1 Derivatives of 2-(1-benzyl-1h-pyrazolo (3, 4-b)pyridine-3yl) -5-(4-pyridinyl)-4-pyrimidine amine and the use thereof as guanylate cyclase stimulators
03/02/2005EP1509218A1 Peptide deformylase inhibitors
03/02/2005EP1412353B1 Imidazopyridinones as p38 map kinase inhibitors
03/02/2005EP1278741B1 Muscarinic agonists
03/02/2005EP1238979B1 Fused heterotricyclic compounds, process for preparing the compounds and drugs containing the same
03/02/2005EP0919553B1 cis-SUBSTITUTED AMINOCYCLOPROPANE DERIVATIVES
03/02/2005EP0871448B1 Aryl and heteroaryl quinazoline compounds which inhibit csf-1r receptor tyrosine kinase
03/02/2005EP0824530B1 Aryl glycinamide derivatives, methods of producing these substances and pharmaceutical compositions containing such compounds
03/02/2005CN1589273A The use of anti-histaminics for acute reduction of elevated intracranial pressure
03/02/2005CN1589271A Fused heterocyclic succinimide compounds and analogs thereof as modulators of nuclear hormone receptor function
03/02/2005CN1589153A Preventives/remedies for urinary disturbance
03/02/2005CN1589148A Succinic acid salts of 5, 8, 14-triazatetracyclo'10.3.1.0 less than2, 11greater than.0 less than 4, 9 greater than-hexadeca-2(11), 3, 5, 7, 9-pentaene and pharmaceutical compositions thereof
03/02/2005CN1589145A αv整联蛋白受体拮抗剂 αv integrin receptor antagonists
03/02/2005CN1191253C Crystal modification(of 8-cyano-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo-[4.3.0] nonan-8-y1)-6 Fluoro-1,4-dinydro-4-oxo-3-quinoline carboxylic
03/02/2005CN1191251C Intermediate for preparing cyclopentane formamide compound and its preparation method
03/02/2005CN1191249C Quinoline and quinazoline compound for treating benign prostatic hyperplasia specially
03/02/2005CN1191236C Substituted 6,6-Hetero-dicycloderivative
03/02/2005CN1191234C Process for producing piperidine compound
03/01/2005US6861525 Reducing the corresponding glyoxylamide compound with phosphorus bormide or chloride
03/01/2005US6861440 Antidiabetic agents
03/01/2005US6861437 Substituted imidazo [1,2-a] pyridine derivatives
03/01/2005US6861436 Useful against multidrug resistant cancer cells
03/01/2005US6861430 β-carboline derivatives and its pharmaceutical use against depression and anxiety
03/01/2005US6861425 Benzimidazole compounds as ORL1-receptor agonists
03/01/2005US6861423 Methods of treating p38 kinase-mediated disorders with pyrido[2,3-d]pyrimidin-7-one compounds
02/2005
02/24/2005WO2005016928A1 Imidazopyridine derivatives
02/24/2005WO2005016927A1 Nitrogenous condensed-ring compound and use thereof as hiv integrase inhibitor
02/24/2005WO2005016926A1 Pyrido [3,4-d] pyrimidine derivatives as matrix metalloproteinase-13 inhibitors
02/24/2005WO2005016925A1 Azaquinazoline derivatives
02/24/2005WO2005016924A1 7-azaindole derivatives as cox2 inhibitors
02/24/2005WO2005016913A1 Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
02/24/2005WO2005016892A1 Gabanergic modulators
02/24/2005WO2005016884A1 Cyclopropyl derivatives as nk3 receptor antagonists
02/24/2005WO2005016875A2 Geometrically restricted 3-cyclopentylidene-1,3-dihydroindol-2-ones as potent protein kinase inhibitors
02/24/2005WO2005016862A1 Substituted arylalkanoic acid derivative and use thereof
02/24/2005WO2005016255A2 Substituted tetrahydroquinolines, phenylacetic acids and benzoic acids as hepatocyte nuclear factor 4 (hnf-4 ) modulator compounds
02/24/2005WO2005016245A2 Compounds having inhibitive activity of phosphatidylinositol 3-kinase and methods of use thereof
02/24/2005WO2005016235A2 Combined use of impdh inhibitors with toll-like receptor agonists
02/24/2005WO2005016000A1 Derivatives of cyclic quinone and uses thereof
02/24/2005WO2004099168A3 Substituted carboxylic acids
02/24/2005WO2004078712A3 Isoquinoline derivatives and methods of use thereof
02/24/2005US20050043546 protection of 1-(N-t-butoxycarbonyl)-4-aminomethylene-pyrrolidin-3-one with t-butoxycarbonyl anhydride, to afford 1-(N-t-butoxycarbonyl)-4-(N-t-butoxycarbonyl)aminomethylene-pyrrolidin-3-one, used as chemical intermediates for naphthyridine carboxylic acid derivatives having antibacterial activity
02/24/2005US20050043535 4-(Piperidyl-and pyrrolidyl-alkyl-ureido)-quinolines as urotensin II receptor antagonists
02/24/2005US20050043366 Antiinflamamtory agents; immunology disorders; autoimmune diseases; antiallergens; aids viricides; antiarthritic agents; muscular disorders; Parkinson's disease; Alzheimer's disease; kidney damage
02/24/2005US20050043358 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists
02/24/2005US20050043354 Substance P antagonist
02/24/2005US20050043348 Phenyl-substituted imidazopyridines
02/24/2005US20050043346 Pyridylpyrrole derivatives active as kinase inhibitors
02/24/2005US20050043337 Selective beta3 adrenergic agonists
02/24/2005US20050043336 Quinazoline derivatives as antitumor agents
02/24/2005US20050043331 Substituted 3-(2,5-disubstituted)pyridyl-4-aryl pyrroles for treating inflammatory diseases
02/24/2005US20050043330 Antiinflammation agents
02/24/2005US20050043326 Compounds
02/24/2005US20050043323 Pyrimidylpyrrole derivatives active as kinase inhibitors
02/24/2005US20050043309 7-[4-(4-naphthalen-1-yl-piperazin-1-yl)-butoxy]-3,4-dihydro-1H-[1,8]naphthyridin-2-one; use in the treatment of central nervous system disorders, bipolar disorder in a human; chemical synthesis
02/24/2005US20050043308 Process for total synthesis of ecteinascidins and intermediates therefor
02/24/2005US20050043212 Drug design of a preferential enzyme inhibitor of the p38 Mitogen-activated protein kinase alpha isoform
02/24/2005CA2743534A1 Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor
02/24/2005CA2577239A1 Nitrogen-containing fused ring compound and use thereof as hiv integraseinhibitor
02/24/2005CA2535665A1 Substituted arylalkanoic acid derivative and use thereof
02/24/2005CA2535416A1 Imidazopyridine derivatives
02/24/2005CA2535406A1 Gabanergic modulators
02/24/2005CA2528938A1 Compounds having inhibitive activity of phosphatidylinositol 3-kinase and methods of use thereof
02/23/2005EP1507779A1 Inhibitors of jak and cdk2 protein kinases
02/23/2005EP1507778A1 Anti-tumour polycyclic carboxamides
02/23/2005EP1507777A2 Process for preparing crystalline form i of cabergoline
02/23/2005EP1507776A1 2-oxo-1,3,4-trihydroquinazolinyl derivatives for the treatment of cell proliferation-related disorders
02/23/2005EP1507765A2 Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
02/23/2005EP1507504A1 Cycloalkyl inhibitors of potassium channel function
02/23/2005EP1395583B1 New phenylpiperazines
02/23/2005EP1274710B1 Novel heteroaryl-diazabicycloalkanes
02/23/2005EP1177177B1 Substituted 4-oxo-quinoline-3-carboxamides: gaba brain receptor ligands
02/23/2005EP1133497B1 Crystal modification b of 8-cyano-1- cyclopropyl -7-(1s,6s-2, 8-diazabicyclo 4.3.0]nonan -8-yl)-6- fluoro-1,4- dihydro-4- oxo-3-quinoline carboxylic acid
02/23/2005EP0876337B1 New lh-rh antagonists with improved effectiveness
02/23/2005CN1585772A Chemokine receptor antagonists and methods of use thereof
02/23/2005CN1585754A Quinazoline derivatives as antitumor agents
02/23/2005CN1585751A 喹啉化合物 Quinoline compound
02/23/2005CN1585634A Pharmaceutical composition comprising an adenosine A1/A2 agonist and a sodium hydrogen exchanger inhibitor
02/23/2005CN1583744A Pirenzepine organic acid salt and eye drops for treating myopia
02/23/2005CN1583724A 7-(4, 4-dimethyl 3-aminomethylpentazane-1-radicle) substituted, quinoline carboxylic acid derivative and its preparation
1 ... 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 ... 646